The FDA Vaccines & Related Biological Products Advisory Committee (VRBPAC) is meeting today to discuss the safety and efficacy of Dynavax Technologies Corporation’s (NASDAQ:DVAX) experimental …
Sarepta’s $12+ Million 2Q Beat Sarepta Therapeutics Inc (NASDAQ:SRPT) Duchenne muscular dystrophy (DMD) drug Exondys 51 (eteplirsen) has outclassed expectation, leading the biotech …
Dynavax Technologies Corporation (NASDAQ:DVAX) announced the presentation of findings in patients with metastatic melanoma in the dose escalation phase of an ongoing Phase …
Dynavax Technologies Corporation (NASDAQ:DVAX) reported financial results for the fourth quarter and year ended December 31, 2016. The net loss for the year …
Dynavax Technologies Corporation (NASDAQ:DVAX) investors cheer the news that the FDA has accepted for review Dynavax’s responses to the Complete Response Letter (CRL) …
Dynavax Technologies Corporation (NASDAQ:DVAX) announced that it is reshaping its strategy and operations to prioritize its emerging clinical and preclinical immuno-oncology portfolio. The …
That was a rough week for investors in Dynavax Technologies Corporation (NASDAQ:DVAX), after the biotech firm announced on Monday, November 14th that it had received …
Monday turned out to be a nightmare for shareholders of biotech companies Dynavax Technologies Corporation (NASDAQ:DVAX) and Puma Biotechnology Inc (NYSE:PBYI), as the stocks …
After a long debate, Dynavax Technologies Corporation’s (NASDAQ:DVAX) hepatitis B vaccine Heplisav ended up sinking the company’s shares by nearly 70% in pre-market trading. …
